AOP-Wiki

API

All KERs

Showing 1151 to 1175 of 3119 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1840	1457: EMT	1587: Fibroproliferative airway lesions	Jan 30, 2019	Jan 30, 2019	1 AOP 280: α-diketone-induced bronchiolitis obliterans
2154	1457: EMT	1458: Pulmonary fibrosis	Jul 9, 2020	Jul 9, 2020	1 AOP 347: Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis
2614	1457: EMT	1982: Metastasis, Breast Cancer	Mar 22, 2022	Sep 26, 2023	1 AOP 443: DNA damage and mutations leading to Metastatic Breast Cancer
3200	1457: EMT	1651: Resistant gastric cancer	Apr 23, 2024	Apr 23, 2024	1 AOP 298: Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer
3204	1457: EMT	2013: Airway remodeling	May 1, 2024	May 1, 2024	1 AOP 452: Adverse outcome pathway of PM-induced respiratory toxicity
3306	1457: EMT	885: Increase, Cancer	Jul 18, 2024	Jul 18, 2024	1 AOP 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT
3391	2251: Increased E2 availability	1065: Activation, ERα	Nov 15, 2024	Nov 21, 2024	3 AOPs 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level 561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol 565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha
2880	2126: ERa inactivation	2127: Increased adipocyte size	Apr 6, 2023	Apr 6, 2023	1 AOP 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity
2881	2126: ERa inactivation	2128: Increased adipocyte numbers	Apr 6, 2023	Apr 6, 2023	1 AOP 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity
2906	2126: ERa inactivation	2130: increased lipid accumulation	May 4, 2023	May 4, 2023	1 AOP 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity
2929	2126: ERa inactivation	179: Decrease, Fatty acid β-oxidation	May 25, 2023	May 25, 2023	1 AOP 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome
2930	2126: ERa inactivation	1115: Increase, ROS	May 25, 2023	May 25, 2023	1 AOP 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome
1273	1217: Sensory Airway Irritation	1221: Cough, Dyspnea, Sneezing, Acute respiratory effect	Nov 29, 2016	Dec 3, 2016	None
1357	1273: Expression of Collagen	1275: Collagen Deposition	Feb 15, 2017	Feb 15, 2017	None
2971	2153: Expression of factors ruling proliferation, modified	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	Jul 27, 2023	Apr 28, 2025	1 AOP 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation
2439	1905: eya1 expression, inhibited	1825: Increase, Cell death	Jul 14, 2021	Aug 22, 2021	1 AOP 410: GSK3beta inactivation leading to increased mortality via defects in developing inner ear
2686	1559: Smaller and morphologically distorted facial cartilage structures	947: Increase, Early Life Stage Mortality	Jun 30, 2022	Apr 13, 2023	1 AOP 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development
1165	1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo	1133: Hemostasis, Depletion from blood of fully functional carboxylated clotting factors	Nov 29, 2016	Dec 3, 2016	1 AOP 187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1169	1130: Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)	1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis	Nov 29, 2016	Dec 3, 2016	1 AOP 187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1749	1528: Fatty Acid Beta Oxidation, Decreased	861: Decreased, Ketogenesis (production of ketone bodies)	Jun 11, 2018	Jun 11, 2018	1 AOP 6: Antagonist binding to PPARα leading to body-weight loss
266	240: Feminisation or incomplete development, Primary and accessory male sex organs	337: N/A, Impairment of reproductive capacity	Nov 29, 2016	Dec 3, 2016	1 AOP 19: Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)
3296	2241: Ferroptosis related pathways activation	1928: increased，Vascular endothelial dysfunction	Jul 9, 2024	Jul 9, 2024	1 AOP 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways
2352	1866: Hypofibrinolysis	1867: Bradykinin, activated	Apr 20, 2021	Apr 20, 2021	1 AOP 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation
2356	1866: Hypofibrinolysis	1496: Increased proinflammatory mediators	Apr 20, 2021	Feb 7, 2023	1 AOP 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation
3707	2399: FGF10/FGFR2-IIIb signaling in genital tissue, reduced	2400: Preputial epithelial morphogenesis, disrupted	Dec 16, 2025	Dec 16, 2025	1 AOP 619: Androgen receptor antagonism leads to delayed preputial seperation via reduced fibroblast growth factor in genital-tubercle tissues

Key Event Relationships (KERs)

All KERs